Neovasc Inc

Neovasc — Investor Presentation (October 2010)

28 slides from Neovasc's investor presentation, October 2010

  1. Slide 1: Neovasc Inc.

    Neovasc Inc. October 2010 Alexei Marko, CEO Chris Clark, CFO

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo

  3. Slide 3: Neovasc at-a-Glance

    Neovasc at-a-Glance • Medical device company focused on innovative products to treat heart disease and related conditions • Two key product lines with large growth potential : – Neovasc Reducer™ for treatment of refractory angina – Implantable biological tissue and services for minimally invasive he

  4. Slide 4: Neovasc Key Products

    Neovasc Key Products Neovasc Reducer™ Treatment for Refractory Angina Implantable Biological Tissue Components for emerging new market in Transcatheter Heart Valves and other products

  5. Slide 5: Reducer Summary

    Reducer Summary Treats Refractory Angina • Inadequate blood flow to heart muscle that cannot be managed through conventional drug, catheter or surgical therapy • Causes constant and severe heart pain and significant disability that negatively impacts quality of life • Large affected population is gr

  6. Slide 6: Reducer Market Opportunity

    Reducer Market Opportunity • Estimated selling price $3,000 - $5,000 • ~ 2 million existing “no option” refractory angina patients in US & Europe ($6B potential market) • ~400,000 new “no option” patients diagnosed annually ($1.2B potential market) • ~ 1 million patients/year in US & Europe undergo

  7. Slide 7: Reducer – The Problem

    Reducer – The Problem Oxygenated blood feeds heart muscle through coronary arteries inflow Chronically diseased arteries restrict blood flow to capillaries that feed heart muscle Ð Severe Angina Pain outflow De-oxygenated blood from heart muscle collected in coronary sinus

  8. Slide 8: Reducer – How It Works

    Reducer – How It Works Reducer restricts outflow of blood from coronary veins, forcing oxygenated blood deeper into the heart muscle where it reaches oxygen-starved ischemic areas Improved penetration of blood to feed heart muscle Ð Reduced Angina Pain Reducer

  9. Slide 9: Reducer Procedure

    Reducer Procedure • Treatment by narrowing coronary sinus based on a surgical procedure performed in 1960’s (Beck Procedure) • Beck Procedure reported excellent results but is no longer performed due to invasiveness of the surgery • Neovasc Reducer achieves same narrowing, but using modern catheter-

  10. Slide 10: Reducer Clinical Results

    Reducer Clinical Results Compelling clinical data from first human trial (15 patients, 3 centers) • Six-month data published in JACC, May 2007 demonstrated safety and significant improvement of angina symptoms • Three-year follow-up data confirms excellent long-term safety and durability of treatmen

  11. Slide 11: Reducer COSIRA Trial for CE Mark Application

    Reducer COSIRA Trial for CE Mark Application COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) Double-blind, randomized, sham-controlled, multicenter, prospective trial • 124 patients • Randomized 1:1 to blinded treatment and sham control arms • Primary endpoint: Efficacy @ 6-months

  12. Slide 12: Advisors Include Key Opinion Leaders

    Advisors Include Key Opinion Leaders Leaders in interventional cardiology and refractory angina are working on the Reducer program – enthusiasm evident at TCT Live Case • Dr. Martin Leon (Columbia University Medical Center, NYC) • Dr. Tim Henry (Minneapolis Heart Institute) • Dr. Elazer Edelman (Har

  13. Slide 13: Reducer Commercialization Timeline

    Reducer Commercialization Timeline • Commercial product completed • Europe: COSIRA to provide data for CE-mark and European launch (early 2012) • US: FDA trial and approval process (PMA) will be initiated following European CE-mark approval (commence mid 2012)

  14. Slide 14: Implantable Biological Tissue Products

    Implantable Biological Tissue Products • Proprietary Neovasc process creates implantable, biocompatible tissue that retains strength and physical characteristics of natural tissue • Developed specifically for surgical heart valve applications • Adapted for general surgical use as a patch or reinforc

  15. Slide 15: Rapid Growth in Heart Valve Applications

    Rapid Growth in Heart Valve Applications Neovasc is the leading supplier of biological leaflet material to companies developing transcatheter heart valves • Acquisitions of Ventor, Corevalve and Evalve in 2009 spurred rapid growth of sector • PARTNER trial results (Sept 2010) demonstrate 20% lower m

  16. Slide 16: Rapid Growth in Heart Valve Applications

    Rapid Growth in Heart Valve Applications • Transcatheter aortic heart valve market is currently ~$200 million and is projected to exceed $2 billion by 2014 • Transcatheter mitral valve replacement market is projected to grow from nil to $1billion over next 5 years As a leading supplier of heart valv

  17. Slide 17: Other Applications

    Other Applications • Artificial heart components • Covered stent grafts • Specialty vascular devices • Vascular surgical patches (LeMaitre Vascular’s Xenosure™) • Surgical patches for non-vascular use

  18. Slide 18: Tissue Development & Manufacturing

    Tissue Development & Manufacturing • Services specifically for biological tissue-based vascular devices – Product development (design, prototyping, testing, transfer to manufacture, etc.) – Tissue product manufacture (valve assembly, sterilization, etc.) • State-of-the-art facility and highly experi

  19. Slide 19: Neovasc Competitive Advantages

    Neovasc Competitive Advantages • Established valve & biological tissue device manufacturing & associated operations are already generating positive cash flow • Proven biological tissue process & established high volume production • Expertise in multiple aspects of vascular device & heart valve produ

  20. Slide 20: 2009 Strategy: Refocus Post-Acquisition

    2009 Strategy: Refocus Post-Acquisition Refocus and rationalize after acquisition of two start-up companies: 1. Streamline operations to reduce cost base 9 Maximize efficiency - eliminate all unnecessary costs and overheads 2. Aggressively grow tissue business revenues 9 Develop strategic partnershi

  21. Slide 21: 2010 Strategy: Break-Even, Build Value

    2010 Strategy: Break-Even, Build Value Biological Tissue Product Lines • Continue to expand biological tissue business with focus on high value industry customers; fast growing segments such as new transcatheter valve products • Targeting >$4 million in revenue and break-even for tissue business Neo

  22. Slide 22: 2009 / 2010 Financial Results

    2009 / 2010 Financial Results Revenue 1200 1000 800 Actual $000s 600 Projected 400 200 0 Q1 F09 Q2 F09 Q3 F09 Q4 F09 Q1 F10 Q2 F10 Q3 F10 Q4 F10 Quarter

  23. Slide 23: 2009 / 2010 Financial Results

    2009 / 2010 Financial Results Expenses excluding Stock Compensation Expense 2000 1800 1600 1400 1200 R&D 1000 $s G&A S&M 800 600 400 200 0 Q1 F09 Q2 F09 Q3 F09 Q4 F09 Q1 F10 Q2 F10 Quarters

  24. Slide 24: 2011 – Looking Forward

    2011 – Looking Forward 1. Continued growth in revenues from tissue business (target $5M) – Expect steady growth over next 12 months with upside potential as customers’ products enter market 2. Complete COSIRA trial for Reducer and file CE-mark application to allow sale in Europe – Preliminary COSIRA

  25. Slide 25: Management and Board

    Management and Board Management • Alexei Marko – CEO and Board Member • Chris Clark – CFO • Brian McPherson - COO Board of Directors • Paul Geyer (former CEO, Mitroflow) • Steven Rubin (Frost Group, OPKO) • Dr. Jane Hsiao (Frost Group, OPKO) • Dr. William O’Neill (Interventional Cardiologist) • Doug

  26. Slide 26: Capitalization & Trading

    Capitalization & Trading • 37.7m (issued and outstanding) Shares outstanding • 44.8m (fully diluted) Public listing • TSX-V NVC • Frost Group (Dr. Phillip Frost) Key investors • Company management Float and trading • ~75% of shares held by management and insiders • $2.0m financing completed in April

  27. Slide 27: Neovasc: A Promising Opportunity

    Neovasc: A Promising Opportunity Cash Generating • Biological tissue business is growing, has significant upside potential & forecast to be profitable in 2011 – Contributions minimize funding requirements for new product development Value Generating • Pivotal trial (COSIRA) underway for Neovasc Redu

  28. Slide 28: Thank you

    Thank you Qs

Neovasc — Investor Presentation (October 2010) on 6ix